CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM

A Major Breakthrough in Blood Clot Prevention

Cadrenal Therapeutics, a biopharmaceutical company dedicated to advancing anticoagulation therapy, has made a significant move by joining the Corporate Council of the Anticoagulation Forum (AC Forum). This partnership marks a substantial step forward in the quest to improve the quality and safety of blood clot prevention treatments. Here, we delve into the details of this critical collaboration and its potential impact on patient care.

The Importance of Anticoagulation Therapy

Anticoagulation therapy is a crucial aspect of modern medicine, particularly for patients with implanted cardiac devices or those suffering from rare cardiovascular conditions. These treatments are designed to prevent the formation of blood clots, which can lead to heart attacks, strokes, and other life-threatening conditions. However, the current landscape of anticoagulation therapy faces several challenges, including the need for more effective and safer alternatives to existing treatments like warfarin.

Cadrenal Therapeutics: A Leader in Innovation

Cadrenal Therapeutics is at the forefront of this innovation, developing tecarfarin—a new vitamin K antagonist (VKA) designed to address the limitations of current anticoagulant medications. Tecarfarin is particularly promising for patients with implanted cardiac devices, such as ventricular assist devices (VADs), and those with end-stage kidney disease (ESKD) and atrial fibrillation (AFib). The company's commitment to advancing tecarfarin through clinical trials and regulatory approvals reflects its dedication to improving patient outcomes.

The Role of the Anticoagulation Forum

The Anticoagulation Forum (AC Forum) is the largest professional organization of anticoagulation specialists. With over 15,000 healthcare professionals in its network, the AC Forum is committed to advancing the quality and safety of chronic anticoagulation care globally. By joining the Corporate Council, Cadrenal Therapeutics gains access to this extensive network of experts, allowing for collaborative efforts to address unmet clinical needs and share cutting-edge research.

Key Benefits of the Partnership

This strategic partnership offers several key benefits:

• Access to Network: Cadrenal Therapeutics will collaborate with the AC Forum's 15,000 healthcare professional members, potentially enhancing market penetration and improving the effectiveness of their anticoagulation therapy.

• Enhanced Visibility: The partnership will increase Cadrenal's visibility and credibility in the anticoagulation therapy space, making it a more prominent player in the industry.

• Shared Clinical Insights: By working together, Cadrenal and the AC Forum can share valuable insights and research findings, ultimately leading to better patient outcomes.

• Educational Initiatives: The partnership will promote educational initiatives aimed at improving the understanding and use of anticoagulation therapies among healthcare professionals. This is particularly important given the complexities of anticoagulation management.

Addressing Unmet Clinical Needs

One of the primary objectives of this partnership is to address unmet clinical needs in anticoagulation therapy. For instance, tecarfarin may prove invaluable for patients where warfarin is not providing recommended anticoagulation due to genetic warfarin resistance or renal impairment. By addressing these gaps, Cadrenal and the AC Forum aim to provide more comprehensive care for patients requiring chronic anticoagulation.

Securing Administrative Leadership Support

A recent publication in the Journal of American College of Clinical Pharmacy highlights the challenges in securing administrative leadership support for anticoagulation stewardship programs. This issue is crucial because it often hinders the implementation of effective anticoagulation management strategies. The AC Forum has provided a structured approach to guide clinicians advocating to leadership for stewardship programs, which could be particularly beneficial in the context of this partnership with Cadrenal.

Upcoming Webinars and Conferences

The Anticoagulation Forum has several upcoming events that are expected to further highlight the importance of this partnership:

• Webinar: Differences in Quality of Anticoagulation Care Delivery According to Ethnoracial Group - Scheduled for July 11, 2024, this webinar will explore the nuances of delivering anticoagulation therapy in the United States, focusing on the differences in quality of care across ethnoracial groups and their impact on patient outcomes. This event underscores the AC Forum's commitment to addressing disparities in healthcare.

• Anticoagulation Boot Camp - Taking place on October 18-19, 2024, this virtual boot camp aims to provide comprehensive training for healthcare professionals on anticoagulation management. With Cadrenal’s involvement, this event is expected to include discussions on the latest advancements in anticoagulation therapy.

• AC Forum National Conference - Scheduled for April 3-5, 2025, in Washington, D.C., this conference will bring together leading experts in the field of anticoagulation to discuss recent advancements and challenges. The conference is expected to be a key platform for Cadrenal to share its research and findings with the broader community.

Conclusion

The partnership between Cadrenal Therapeutics and the Anticoagulation Forum represents a significant milestone in the quest to improve blood clot prevention treatments. By combining Cadrenal’s innovative approach to anticoagulation therapy with the AC Forum’s extensive network of healthcare professionals, this collaboration has the potential to address unmet clinical needs and enhance patient outcomes. As we move forward, it will be exciting to see the tangible results of this partnership, particularly with regards to the development and implementation of tecarfarin.

---

References

• Anticoagulation Forum: For more information on the Anticoagulation Forum and its upcoming events, visit their website.

• Cadrenal Therapeutics Joins Corporate Council of Anticoagulation Forum: For details on Cadrenal’s partnership with the AC Forum, refer to the press release from Cadrenal Therapeutics.

• Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update: To learn more about Cadrenal’s advancements in tecarfarin development, read their corporate update from August 7, 2024.